Sigilon Therapeutics
Robert Langer, Sc.D., has served as a member of our board of directors since 2016. Since 2005, Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has served on the boards of directors of Abpro Corporation since 2016, Frequency Therapeutics, Inc. since 2016, Rubius Therapeutics, Inc. since 2014, Moderna, Inc. since 2010, and Lyra Therapeutics, Inc. since 2006. Dr. Langer has previously served on the boards of directors of Puretech Health plc, Momenta Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Kala Pharmaceuticals, Inc., Fibrocell Science, Inc., and Millipore Corp. Dr. Langer holds a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University.
This person is not in the org chart
This person is not in any offices
Sigilon Therapeutics
2 followers
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.